Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082875 | 1.00 | NAAA (0.47) | NAAAPPARAFAAHGFERLTB4R | |
| SCHEMBL345275 | 0.89 | NAAA (0.57) | NAAAPPARAFAAHFKBP1AIDH1 | |
| SCHEMBL6334745 | 0.89 | NAAA (0.57) | NAAAPPARAFAAHFKBP1AIDH1 | |
| SCHEMBL345276 | 0.89 | NAAA (0.57) | NAAAPPARAFAAHFKBP1AIDH1 | |
| SCHEMBL4611151 | 0.87 | NAAA (0.46) | NAAAPPARAFAAHLTB4RLTB4R2 | |
| SCHEMBL2304021 | 0.87 | NAAA (0.46) | NAAAPPARAFAAHLTB4RLTB4R2 | |
| SCHEMBL13725782 | 0.84 | NAAA (0.46) | NAAAPPARAFAAHHDAC1IDH1 | |
| SCHEMBL13725779 | 0.84 | NAAA (0.46) | NAAAPPARAFAAHHDAC1IDH1 | |
| SCHEMBL2872894 | 0.84 | NAAA (0.52) | NAAAFAAHHDAC1FKBP1ANPC1 | |
| SCHEMBL2872897 | 0.84 | NAAA (0.52) | NAAAFAAHHDAC1FKBP1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981913-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-7902218-B2 | Inhibit production of A beta -peptide; neurological disorders, Alzheimer's disease; (S)-2-((S)-3-Acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902218-B2 | Inhibit production of A beta -peptide; neurological disorders, Alzheimer's disease; (S)-2-((S)-3-Acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902218-B2 | Inhibit production of A beta -peptide; neurological disorders, Alzheimer's disease; (S)-2-((S)-3-Acetamido-3-((R)-sec-butyl)-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-02 | — | — | US | disclosed |
| US-7745470-B2 | Isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080153868-A1 | Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
| US-7388007-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388007-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388007-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060229309-A1 | Novel isophthalates as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-12 | — | — | US | disclosed |
| WO-2006099352-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099352-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006026204-A2 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006026204-A2 | NOVEL GAMMA-LACTAMS AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | THOMPSON LORIN A III | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153868-A1 | Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors | BACE1, APP, BACE2 | NAAA 462/4885PPARA 3454/4885FAAH 752/4885 |
| US-20060046984-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, BACE2, APP | NAAA 301/4885PPARA 3700/4885FAAH 1469/4885 |
| US-20100222581-A1 | NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | NAAA 744/4885PPARA 3311/4885FAAH 352/4885 |
| US-20060229309-A1 | Novel isophthalates as beta-secretase inhibitors | BACE1, APP, BACE2 | NAAA 744/4885PPARA 3311/4885FAAH 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.